REGISTRATION IN ISRAEL: GUIDELINES

2 November 1992

The Pharmaceutical Section of the Manufacturers' Association of Israel, which represents over 201 drug companies, has sponsored the publication in English of the Guidelines for Filing Applications for Registration of Medicinal Products in Israel.

The publication provides information on the dossier to be submitted in support of a registration application, and also for renewals and amendments. Full instructions are provided on: the documentation which is required from the country of origin; data on the method of manufacture and quality control of the active ingredients and of the finished form; stability data; pharmacotechnical data by type of dosage form; prescribing information for the physician; the patient package insert; packaging; and labeling. The scope of the preclinical and clinical data required is also detailed.

A series of annexes sets out guidelines for bioavailability testing, requirements for registration of various types of generic products, model texts for the patient package insert (these are now required to be printed in three languages - Hebrew, Arabic and English), and the exact content of the various application forms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight